J&J Risperdal Pituitary Tumor Risk To Be Evaluated In FDA Claims Study
Executive Summary
FDA's Division of Psychiatry Products and Office of Surveillance & Epidemiology are planning a study to determine if Johnson & Johnson's Risperdal (risperidone) has an increased risk of pituitary adenoma versus other antipsychotics